Hypolipidemic therapy for the metabolic syndrome

Pharmacological Research : the Official Journal of the Italian Pharmacological Society
Andrea CignarellaChiara Bolego

Abstract

The metabolic syndrome appears to affect a significant proportion of the population and is associated with increased risk for development of cardiovascular disease as well as of type-2 diabetes. No single treatment for the metabolic syndrome as a whole yet exists. While the primary management of patients with the metabolic syndrome involves healthy lifestyle promotion, the atherogenic dyslipidemia is a primary target for cardiovascular disease risk reduction in these patients. Statin therapy provides effective reduction of LDL-cholesterol, which represents the primary therapeutic goal of lipid-lowering therapy in patients at risk for cardiovascular disease. Fibrates in turn are effective in normalizing lipid levels (mainly triglycerides and HDL-cholesterol) in patients with the metabolic syndrome and may improve insulin resistance. Whereas statins remain the drug of choice for patients who need to achieve the LDL-cholesterol goal, fibrate therapy may represent an alternative for those with low HDL-cholesterol and high triglyceride levels. The simultaneous use of fibrates could be indicated in patients whose LDL-cholesterol is controlled by statin therapy but whose HDL-cholesterol and/or triglycerides are still inappropriate. Su...Continue Reading

References

Feb 9, 2000·Pharmacology & Therapeutics·A CorsiniF Bernini
Jul 6, 2000·Circulation·UNKNOWN Bezafibrate Infarction Prevention (BIP) study
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jul 4, 2001·JAMA : the Journal of the American Medical Association·M A AlbertUNKNOWN PRINCE Investigators
May 25, 2002·Angiology·Evagelos RizosDimitri P Mikhailidis
Oct 19, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Thomayant PrueksaritanontJiunn H Lin
Dec 4, 2002·JAMA : the Journal of the American Medical Association·Hanna-Maaria LakkaJukka T Salonen
Dec 25, 2002·Journal of Cardiovascular Pharmacology·Jean DucobuHerve Salomon
Feb 28, 2003·Proceedings of the National Academy of Sciences of the United States of America·Ouliana ZiouzenkovaJorge Plutzky
Apr 30, 2003·Diabetes Care·Sander J RobinsUNKNOWN Veterans Affairs HDL Intervention Trial (VA-HIT)
Jun 14, 2003·The American Journal of Cardiology·Nathan D WongG Rhys Williams
Oct 17, 2003·Current Drug Targets. Inflammation and Allergy·A CabreroM Vázquez
Nov 5, 2003·Expert Opinion on Pharmacotherapy·Harold Bays, Evan A Stein
Apr 9, 2004·The New England Journal of Medicine·Margaret E BrousseauDaniel J Rader
May 6, 2004·International Journal of Clinical Pharmacology and Therapeutics·J WysockiZ Kalina
Oct 8, 2004·The British Journal of Nutrition·Paul Trayhurn, I Stuart Wood
Dec 28, 2004·The American Journal of Cardiology·Peter H Jones, Michael H Davidson
Jan 7, 2005·The New England Journal of Medicine·Steven E NissenUNKNOWN Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators
Jan 12, 2005·The American Journal of Cardiology·Paul L CannerMark E McGovern
Feb 8, 2005·The American Journal of Cardiology·Scott M GrundyJoanne Palmisano
Apr 22, 2005·The New England Journal of Medicine·Göran K Hansson
Apr 30, 2005·Trends in Pharmacological Sciences·Joel P BergerPeter T Meinke
May 25, 2005·Archives of Internal Medicine·Alexander TenenbaumSolomon Behar
May 25, 2005·Archives of Internal Medicine·Marianne ZellerUNKNOWN Observatoire des Infarctus de Côte-d'Or Survey Working Group
Jul 28, 2005·Diabetes·Bart Staels, Jean-Charles Fruchart
Aug 11, 2005·Metabolism: Clinical and Experimental·Vasilios G AthyrosMoses Elisaf
Sep 7, 2005·European Heart Journal·Anton F H StalenhoefWim Wilpshaar

❮ Previous
Next ❯

Citations

Dec 10, 2008·Archives of Medical Research·Aleksandra ZeljkovicSlavica Spasic
Oct 13, 2007·Clinica Chimica Acta; International Journal of Clinical Chemistry·Jing ChenYan-Li He
Sep 23, 2014·Alcohol·Eduardo KarahanianYedy Israel
Oct 26, 2007·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Lorenzo ArnaboldiAlberto Corsini
Apr 1, 2008·Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición·Enrique González-SarmientoE Inmaculada Fernández-Galante
Dec 17, 2008·Clinical Science·Margaret J HillPhilip G McTernan
Mar 7, 2021·International Journal of Molecular Sciences·Giulia Maria CamerinoSabata Pierno
Jan 19, 2007·Journal of Medicinal Chemistry·Carolina CanoManuel Macias-Gonzalez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.